Pyrazinamide resistance, Mycobacterium tuberculosis lineage and treatment outcomes in San Francisco, California

Background: Pyrazinamide (PZA) is a first line agent for the treatment of active tuberculosis. PZA is also considered a potent companion drug for newer regimens under development. There are limited data on the demographic, clinical, and pathogen characteri